[go: up one dir, main page]

AR046083A1 - Derivados de 2 piridona como inhibidores de la elastasa de neutrofilos - Google Patents

Derivados de 2 piridona como inhibidores de la elastasa de neutrofilos

Info

Publication number
AR046083A1
AR046083A1 ARP040103354A ARP040103354A AR046083A1 AR 046083 A1 AR046083 A1 AR 046083A1 AR P040103354 A ARP040103354 A AR P040103354A AR P040103354 A ARP040103354 A AR P040103354A AR 046083 A1 AR046083 A1 AR 046083A1
Authority
AR
Argentina
Prior art keywords
alkyl
alkoxy
optionally further
further substituted
independently selected
Prior art date
Application number
ARP040103354A
Other languages
English (en)
Inventor
Peter Hansen
Karolina Lawitz
Hans Lonn
Antonios Nikitidis
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=29212489&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR046083(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of AR046083A1 publication Critical patent/AR046083A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • C07D213/82—Amides; Imides in position 3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/84—Nitriles
    • C07D213/85—Nitriles in position 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Reivindicación 1: Un compuesto caracterizado porque responde a la fórmula (1), en donde: Y representa CR3 o N; R1 representa H o (C1-6) alquilo; R2 representa: i) CN, NO2, OH, OSO2R47, O-(C2-6) alcanoilo, CO2R47, CHO o (C2-6) alcanoilo; o ii) (C1-6) alcoxi opcionalmente sustituido por OH, (C1-6) alcoxi, CN, NR54R55, CONR54R55, OCOR47 o uno o más átomos de F; o iii) (C3-6) cicloalquilo saturado o parcialmente insaturado opcionalmente sustituido adicionalmente por (C1-6) alquilo; o iv) un anillo heterocíclico (C4-7) saturado o parcialmente insaturado que contiene entre 1 y 3 heteroátomos seleccionados en forma independiente entre O, S(O)m y NR62 opcionalmente sustituido adicionalmente por (C1-6) alquilo; o v) CONR48R49, CONR50NR48R49, C(=NOR52)R53, C(=NH)NHOR52 o NR48R49; o (C2-6) alquenilo o (C2-6) alquinilo; estando dicho grupo alquenilo o alquinilo opcionalmente sustituido adicionalmente por (C1-6) alcoxi o fenilo o un anillo heteroaromático de cinco o seis miembros que contiene entre 1 y 3 heteroátomos seleccionados en forma independiente entre O, S y N; estando dicho anillo fenilo o heteroaromático opcionalmente sustituido adicionalmente por halógeno, CN, (C1-6) alquilo o (C1-6) alcoxi; o vii) (C1-6) alquilo sustituido por uno o más átomos de F; o viii) (C1-6) alquilo sustituido por uno o más grupos seleccionados entre halógeno, OH, oxo, azido, R48R49, (C1-6) alcoxi y (C1-6) alcoxi sustituido por uno o más átomos de F; o ix) (C1-6) alquilo sustituido por fenilo o un anillo heteroaromático de cinco o seis miembros que contiene entre 1 y 3 heteroátomos seleccionados en forma independiente entre O, S y N; estando dicho anillo fenilo o heteroaromático opcionalmente sustituido adicionalmente por halógeno, CN, (C1-6) alquilo o (C1-6) alcoxi; R48 y R49 en forma independiente representan H, OH, (C1-6) alcoxi, (C3-6) cicloalquilo, CHO, (C2-6) alcanoilo, CO2R50, C(X)NR63R64 o (C1-6) alquilo; estando dicho alquilo opcionalmente sustituido adicionalmente por OH, (C1-4) alcoxi, (C3-6) cicloalquilo, CN, o fenilo o un anillo heteroaromático de cinco o seis miembros que contiene entre 1 y 3 heteroátomos seleccionados en forma independiente entre O, S y N; estando dicho alcanoilo opcionalmente sustituido adicionalmente por CN; X representa O o S; o el grupo R48R49 en conjunto representa un anillo azacíclico saturado o parcialmente insaturado de 5 a 7 miembros que incorpora opcionalmente un heteroátomo adicional seleccionado entre O, S y NR56; estando dicho anillo azacíclico opcionalmente sustituido adicionalmente por uno o más sustituyentes seleccionados entre OR57 y (C1-4) alquilo; estando dicho alquilo opcionalmente sustituido adicionalmente por OR57; R3 representa H o F; G1 representa fenilo o un anillo heteroaromático de cinco o seis miembros que contiene entre 1 y 3 heteroátomos seleccionados en forma independiente entre O, S y N; R5 representa H, halógeno, (C1-6) alquilo, CN, (C1-6) alcoxi, NO2, NR14R15, (C1- 3) alquilo sustituido por uno o más átomos de F o (C1-3) alcoxi sustituido por uno o más átomos de F; R14 y R15 en forma independiente representan H o (C1-3) alquilo; estando dicho alquilo opcionalmente sustituido adicionalmente por uno o más átomos de F; n representan un entero 1, 2 ó 3 y cuando n representa 2 ó 3, cada grupo R5 se selecciona en forma independiente; R4 representa H o (C1-6) alquilo, estando dicho alquilo opcionalmente sustituido adicionalmente por OH o (C1-6) alcoxi; o R4 y L están unidos de forma tal que el grupo -R4L representan un anillo azacíclico de 5 a 7 miembros que incorpora opcionalmente un heteroátomo adicional seleccionado entre O, S y NR16; estando dicho anillo opcionalmente sustituido adicionalmente por (C1- 6) alquilo o NR60R61; estando dicho alquilo opcionalmente sustituido adicionalmente por OH; L representa un enlace, O, NR29 o (C1-6) alquilo; donde dicho alquilo incorpora opcionalmente un heteroátomo seleccionado entre O, S y NR16; y estando dicho alquilo opcionalmente sustituido adicionalmente por OH o OMe; G2 representa un sistema de anillo monocíclico seleccionado entre: i) fenilo o fenoxi; ii) un anillo heteroaromático de 5 ó 6 miembros que contiene entre uno y tres heteroátomos seleccionados en forma independiente entre O, S y N; iii) un cicloalquilo (C3-6) saturado o parcialmente insaturado; o iv) un anillo heterocíclico (C4-7) saturado o parcialmente insaturado que contiene uno o dos heteroátomos seleccionados en forma independiente entre O, S(O)p y NR17 y que opcionalmente incorpora además un grupo carbonilo; o G2 representa un sistema de anillo bicíclico en donde cada uno de los dos anillos se selecciona en forma independiente entre: i) fenilo; ii) un anillo heteroaromático de 5 ó 6 miembros que contiene entre uno y tres heteroátomos seleccionados en forma independiente entre O, S y N; iii) un cicloalquilo (C3-6) saturado o parcialmente insaturado; o iv) un anillo heterocíclico (C4-7) saturado o parcialmente insaturado que contiene uno o dos heteroátomos seleccionados en forma independiente entre O, S(O)p y NR17 y que opcionalmente incorpora además un grupo carbonilo; y los dos anillos o bien están fusionados, o están unidos directamente juntos o están separados por un grupo ligante seleccionado entre O, S(O)q o CH2; estando dicho sistema de anillo monocíclico o bicíclico opcionalmente sustituido adicionalmente por entre uno y tres sustituyentes seleccionados en forma independiente entre CN, OH, (C1-6) alquilo, (C1-6) alcoxi, halógeno, NR18R19, NO2, OSO2R38, CO2R20, C(=NH)NH2, C(O)NR21R22, C(S)NR23R24, SC(=NH)NH2, NR31C(=NH)NH2, S(O)SR25, SO2NR26R27, (C1-3) alcoxi sustituido por uno o más átomos de F y (C1-3) alquilo sustituido por SO2R39 o por uno o más átomos de F; o cuando L no representa un enlace, G2 también puede representar H; en cada caso m, p, q, s y t en forma independiente representa un entero 0, 1 ó 2; R18 yR19 en forma independiente representan H, (C1-6) alquilo, formilo, (C2-6) alcanoilo, S(O)tR32 o SO2NR33R34; estando dicho grupo alquilo opcionalmente sustituido adicionalmente por halógeno, CN, (C1-4) alcoxi o COR41R42; R25 representa H, (C1-6) alquilo o (C3-6) cicloalquilo; estando dicho grupo alquilo opcionalmente sustituido adicionalmente por uno o más sustituyentes seleccionados en forma independiente entre OH, CN, CONR35R36, CO2R37, OCOR40, (C3-6) cicloalquilo, un anillo heterocíclico saturado de C4-7 que contiene uno o dos heteroátomos seleccionados en forma independiente entre O, S(O)p y R43 y fenilo o un anillo heteroaromático de 5 ó 6 miembros que contiene entre uno y tres heteroátomos seleccionados en forma independiente entre O, S y N; estando dicho anillo aromático opcionalmente sustituido adicionalmente por uno o más sustituyentes seleccionados en forma independiente entre halógeno, CN, (C1-4) alquilo, (C1-4) alcoxi, OH, CONR44R45, CO2R46, S(O)SR65 y NHCOCH3; R32 representa H, (C1-6) alquilo o (C3- 6) cicloalquilo; R16, R17, R20, R21, R22, R23, R24, R26, R27, R29, R31, R33, R34, R35, R36, R37, R38, 39, R40, R41, R42, R43, R44, R45, R46, R47, R50, R52, R53, R54, R55, R56, R57, R60, R61, R62, R63, R64 y R65 en forma independiente representan H o (C1-6) alquilo; y sus sales aceptables para uso farmacéutico.
ARP040103354A 2003-09-18 2004-09-17 Derivados de 2 piridona como inhibidores de la elastasa de neutrofilos AR046083A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE0302487A SE0302487D0 (sv) 2003-09-18 2003-09-18 Novel compounds

Publications (1)

Publication Number Publication Date
AR046083A1 true AR046083A1 (es) 2005-11-23

Family

ID=29212489

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP040103354A AR046083A1 (es) 2003-09-18 2004-09-17 Derivados de 2 piridona como inhibidores de la elastasa de neutrofilos

Country Status (26)

Country Link
US (1) US20070043036A1 (es)
EP (1) EP1663974B1 (es)
JP (1) JP2007505902A (es)
KR (1) KR20060096995A (es)
CN (1) CN100439339C (es)
AR (1) AR046083A1 (es)
AT (1) ATE420861T1 (es)
AU (1) AU2004272485B2 (es)
BR (1) BRPI0414570A (es)
CA (1) CA2538410A1 (es)
CO (1) CO5670357A2 (es)
DE (1) DE602004019110D1 (es)
ES (1) ES2319300T3 (es)
HK (1) HK1089167A1 (es)
IL (1) IL173986A0 (es)
IS (1) IS8394A (es)
MX (1) MXPA06002723A (es)
NO (1) NO20061700L (es)
RU (1) RU2348617C2 (es)
SA (1) SA04250300B1 (es)
SE (1) SE0302487D0 (es)
TW (1) TW200526579A (es)
UA (1) UA84878C2 (es)
UY (1) UY28513A1 (es)
WO (1) WO2005026124A1 (es)
ZA (1) ZA200602262B (es)

Families Citing this family (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200500341A (en) * 2002-11-12 2005-01-01 Astrazeneca Ab Novel compounds
SE0302486D0 (sv) 2003-09-18 2003-09-18 Astrazeneca Ab Novel compounds
TW200700392A (en) * 2005-03-16 2007-01-01 Astrazeneca Ab Novel compounds
MX2007014114A (es) 2005-05-10 2008-03-14 Intermune Inc Derivados de piridona para modular el sistema de proteina cinasa activada por estres.
CA2618089A1 (en) 2005-08-08 2007-02-15 Argenta Discovery Ltd. Bicyclo[2.2.]hept-7-ylamine derivatives and their uses
GB0516313D0 (en) 2005-08-08 2005-09-14 Argenta Discovery Ltd Azole derivatives and their uses
JP2009509979A (ja) * 2005-09-29 2009-03-12 ユニバーシティ オブ アルバータ グランザイムｂ阻害のための組成物および方法
GB0605469D0 (en) * 2006-03-17 2006-04-26 Argenta Discovery Ltd Multimers of heterocyclic compounds and their use
TW200808763A (en) 2006-05-08 2008-02-16 Astrazeneca Ab Novel compounds I
TW200808771A (en) * 2006-05-08 2008-02-16 Astrazeneca Ab Novel compounds II
US8470859B2 (en) 2006-10-23 2013-06-25 Takeda Pharmaceutical Company Limited Iminopyridine derivative and use thereof
CA2669266C (en) 2006-11-08 2014-04-29 Bristol-Myers Squibb Company Pyridinone compounds
TW200924770A (en) 2007-11-06 2009-06-16 Astrazeneca Ab Novel compounds 089
PL2327693T3 (pl) 2007-12-14 2012-11-30 Pulmagen Therapeutics Asthma Ltd Indole i ich zastosowanie terapeutyczne
JP5314050B2 (ja) 2008-01-23 2013-10-16 ブリストル−マイヤーズ スクイブ カンパニー ４−ピリジノン化合物および癌についてのその使用
US8481569B2 (en) 2008-04-23 2013-07-09 Takeda Pharmaceutical Company Limited Iminopyridine derivatives and use thereof
US8304413B2 (en) 2008-06-03 2012-11-06 Intermune, Inc. Compounds and methods for treating inflammatory and fibrotic disorders
WO2010094956A1 (en) 2009-02-17 2010-08-26 Pulmagen Therapeutics (Inflammation) Limited. Triazolopyridine derivatives as p38 map kinase inhibitors
GB0902648D0 (en) 2009-02-17 2009-04-01 Argenta Discovery Ltd Pharmaceutical compounds and compositions
TW201036957A (en) * 2009-02-20 2010-10-16 Astrazeneca Ab Novel salt 628
KR20120099639A (ko) * 2009-10-02 2012-09-11 아스트라제네카 아베 호중구 엘라스타제의 억제제로서 사용되는 2-피리돈 화합물
GB0918924D0 (en) 2009-10-28 2009-12-16 Vantia Ltd Azaindole derivatives
GB0918923D0 (en) 2009-10-28 2009-12-16 Vantia Ltd Aminothiazole derivatives
GB0918922D0 (en) 2009-10-28 2009-12-16 Vantia Ltd Aminopyridine derivatives
EP2509952A1 (en) * 2009-12-08 2012-10-17 Boehringer Ingelheim International GmbH Process for synthesis of intermediates useful for making substituted indazole and azaindazole compounds
GB201009731D0 (en) 2010-06-10 2010-07-21 Pulmagen Therapeutics Inflamma Kinase inhibitors
EP2740728A4 (en) 2011-08-01 2015-04-01 Sumitomo Dainippon Pharma Co Ltd URACIL DERIVATIVE AND ITS USE FOR MEDICAL PURPOSES
BR112014013177A2 (pt) 2011-12-09 2017-06-13 Chiesi Farm Spa composto, composição farmacêutica e uso de um composto
CN105503861B (zh) 2011-12-09 2017-08-01 奇斯药制品公司 激酶抑制剂
CA2858420A1 (en) 2011-12-09 2013-06-13 Chiesi Farmaceutici S.P.A. Derivatives of 4-hydroxy-1,2,3,4-tetrahydronaphthalen-1-yl urea and their use in the treatment of, inter alia, diseases of the respiratory tract
US9102624B2 (en) 2012-08-23 2015-08-11 Boehringer Ingelheim International Gmbh Substituted 4-pyridones and their use as inhibitors of neutrophil elastase activity
US20140057920A1 (en) 2012-08-23 2014-02-27 Boehringer Ingelheim International Gmbh Substituted 4-pyridones and their use as inhibitors of neutrophil elastase activity
US20140057926A1 (en) 2012-08-23 2014-02-27 Boehringer Ingelheim International Gmbh Substituted 4-pyridones and their use as inhibitors of neutrophil elastase activity
AR092742A1 (es) 2012-10-02 2015-04-29 Intermune Inc Piridinonas antifibroticas
EP3004097B1 (en) 2013-06-06 2018-01-17 Chiesi Farmaceutici S.p.A. Kinase inhibitors
US9221807B2 (en) 2014-02-21 2015-12-29 Boehringer Ingelheim International Gmbh Substituted pyridones and pyrazinones and their use as inhibitors of neutrophil elastase activity
CN106459042B (zh) 2014-04-02 2019-06-28 英特穆恩公司 抗纤维化吡啶酮类
MA43940A (fr) 2015-09-02 2018-12-12 Glaxosmithkline Ip No 2 Ltd Dicarboxamide de pyridinone utilisé comme inhibiteur de bromodomaine
TW201720828A (zh) 2015-11-23 2017-06-16 赫孚孟拉羅股份公司 治療性化合物及組合物以及其使用方法
MA44131A (fr) 2015-12-23 2021-05-26 Chiesi Farm Spa Dérivés de 1-(3-tert-butyl-2h-pyrazol-5-yl or 5-tert-butyl-isoxaol-3-yl)-3-(4-([1,2,4]triazolo[4,3-a]pyridin-6-yloxy)-1,2,3,4-tetrahydro-naphthalenyl) urée et leur utlisation en tant qu'inhibiteurs de p38 mapk
EP3394058B1 (en) 2015-12-23 2020-10-14 Chiesi Farmaceutici S.p.A. N-[3-(3-{4-[[1,2,4]triazolo[4,3-a]pyridin-6-yloxy]-1,2,3,4-tetrahydro-naphthalen-1-yl} -ureido)-phenyl]-methanesulfonamide derivatives and their use as p38 mapk inhibitors
AR107165A1 (es) 2015-12-23 2018-03-28 Chiesi Farm Spa Inhibidores de quinasa
WO2017191098A1 (en) 2016-05-05 2017-11-09 F. Hoffmann-La Roche Ag Pyrazole derivatives, compositions and therapeutic use thereof
CN109890817B (zh) 2016-09-06 2022-06-17 豪夫迈·罗氏有限公司 8-(氮杂环丁烷-1-基)-[1,2,4]三唑并[1,5-a]吡啶基化合物、其组合物和应用方法
MX2019007339A (es) 2016-12-29 2019-09-06 Hoffmann La Roche Compuestos de pirazolopirimidina y metodos de uso de los mismos.
WO2018166993A2 (en) 2017-03-14 2018-09-20 F. Hoffmann-La Roche Ag Pyrazolochlorophenyl compounds, compositions and methods of use thereof
CN110678467B (zh) 2017-05-22 2023-06-13 豪夫迈·罗氏有限公司 治疗化合物和组合物及其使用方法
PE20200341A1 (es) 2017-05-22 2020-02-14 Hoffmann La Roche Composiciones y compuestos terapeuticos y metodos para utilizarlos
US10364245B2 (en) 2017-06-07 2019-07-30 Chiesi Farmaceutici S.P.A. Kinase inhibitors
WO2019139714A1 (en) 2018-01-15 2019-07-18 Genentech, Inc. Pyrazolopyrimidine compounds as jak inhibitors
EP3749697A4 (en) 2018-02-05 2021-11-03 Bio-Rad Laboratories, Inc. CHROMATOGRAPHY RESIN WITH LIGAND MIXED MODE ANIONIC / HYDROPHOBIC EXCHANGE
CN110192947B (zh) * 2019-05-28 2022-01-04 河南省超亚医药器械有限公司 一种小儿肺部热敷贴
CN110192948B (zh) * 2019-05-28 2022-01-04 河南省超亚医药器械有限公司 一种小儿腹部热敷贴
CN114008051B (zh) 2019-06-18 2024-08-13 豪夫迈·罗氏有限公司 Jak激酶的吡唑并嘧啶砜抑制剂及其用途
EP3986900A1 (en) 2019-06-18 2022-04-27 F. Hoffmann-La Roche AG Tetrazole-substituted pyrazolopyrimidine inhibitors of jak kinases and uses thereof
JP2022537354A (ja) 2019-06-18 2022-08-25 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト Ｊａｋキナーゼのピラゾロピリミジンアリールエーテル阻害剤及びその使用
KR20220079527A (ko) 2019-09-17 2022-06-13 메레오 바이오파마 4 리미티드 이식편 거부반응, 폐쇄성 세기관지염 증후군 및 이식편 대 숙주병의 치료에 사용하기 위한 알베레스타트
PT4106757T (pt) 2020-04-16 2023-11-17 Mereo Biopharma 5 Inc Métodos que envolvem o inibidor da elastase neutrofílica alvelestat para o tratamento de doenças respiratórias mediadas pela deficiência de alfa 1 antitripsina
AU2022373971A1 (en) 2021-10-20 2024-04-04 Mereo Biopharma 4 Limited Neutrophil elastase inhibitors for use in the treatment of fibrosis
CN114057630B (zh) * 2021-12-23 2023-06-02 郑州大学 吡非尼酮衍生物及其合成方法和应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9207145D0 (en) * 1991-04-18 1992-05-13 Ici Plc Heterocyclic amides
US5521179A (en) * 1991-04-18 1996-05-28 Zeneca Limited Heterocyclic amides
KR20030070082A (ko) * 2000-12-28 2003-08-27 시오노기세이야쿠가부시키가이샤 칸나비노이드 2형 수용체 친화 작용을 갖는 피리돈 유도체
GB0129260D0 (en) * 2001-12-06 2002-01-23 Eisai London Res Lab Ltd Pharmaceutical compositions and their uses
CA2470813A1 (en) * 2001-12-20 2003-07-03 Bayer Healthcare Ag 1,4-dihydro-1,4-diphenylpyridine derivatives
GB2383326A (en) * 2001-12-20 2003-06-25 Bayer Ag Antiinflammatory dihydropyridines
TW200500341A (en) * 2002-11-12 2005-01-01 Astrazeneca Ab Novel compounds
SE0302486D0 (sv) * 2003-09-18 2003-09-18 Astrazeneca Ab Novel compounds

Also Published As

Publication number Publication date
NO20061700L (no) 2006-04-18
CO5670357A2 (es) 2006-08-31
KR20060096995A (ko) 2006-09-13
TW200526579A (en) 2005-08-16
ZA200602262B (en) 2007-07-25
WO2005026124A1 (en) 2005-03-24
MXPA06002723A (es) 2006-06-06
CA2538410A1 (en) 2005-03-24
RU2006112427A (ru) 2007-11-10
UY28513A1 (es) 2005-04-29
CN1856467A (zh) 2006-11-01
IS8394A (is) 2006-03-31
IL173986A0 (en) 2006-07-05
RU2348617C2 (ru) 2009-03-10
ATE420861T1 (de) 2009-01-15
AU2004272485A1 (en) 2005-03-24
DE602004019110D1 (de) 2009-03-05
HK1089167A1 (en) 2006-11-24
UA84878C2 (ru) 2008-12-10
BRPI0414570A (pt) 2006-11-07
AU2004272485B2 (en) 2008-03-13
SA04250300B1 (ar) 2008-09-07
EP1663974B1 (en) 2009-01-14
JP2007505902A (ja) 2007-03-15
ES2319300T3 (es) 2009-05-06
EP1663974A1 (en) 2006-06-07
SE0302487D0 (sv) 2003-09-18
US20070043036A1 (en) 2007-02-22
CN100439339C (zh) 2008-12-03

Similar Documents

Publication Publication Date Title
AR046083A1 (es) Derivados de 2 piridona como inhibidores de la elastasa de neutrofilos
AR045761A1 (es) Derivados de 2-piridona como inhibidores de elastasa de neutrofilos
AR060875A1 (es) Derivados de 2-piridona como inhibidores de la neutrofilo elastasa humana
AR042024A1 (es) Compuestos farmaceuticos derivados de piridona, pirimidona y pirazinona
AR067327A1 (es) Derivados de piperidina / piperazina
CL2004000076A1 (es) Compuestos derivados de indol, inhibidores de polimerasa, sales; composicion farmaceutica que los comprende; procedimiento de preparacion de dichos compuestos; compuestos intermediarios; y uso del compuesto para tratar una infeccion causada por el vi
CO5640152A2 (es) Composiciones farmaceuticas para inhibidores de la proteasa del virus de la hepatitis c
AR084768A1 (es) Moduladores de la senda de complemento y usos de los mismos
AR069543A1 (es) Derivados bis-(sulfonilamino), composiciones farmaceuticas que los contienen y su uso en terapia.
CY1111628T1 (el) Υποκατεστημενες ενωσεις δικυκλολακταμης
AR055878A1 (es) Derivados de ciclopropanocarboxamida
AR053405A1 (es) Derivados de urea sustituidas, composiciones farmaceuticas y metodos para el tratamiento de cardiopatias
AR060874A1 (es) Compuestos derivados de 2-piperazinona
AR055756A1 (es) Piperidinas sustituidas; procesos de preparacion y su uso como medicamentos
SE0303180D0 (sv) Novel compounds
SE0302232D0 (sv) Novel Compounds
AR058546A1 (es) Derivados de 2- adamantilurea como inhibidores selectivos de 11 beta - hsd1
AR047076A1 (es) Compuestos de pirrolotriazina como inhibidores de tirosina quinasas, composiciones farmaceuticas
AR038703A1 (es) Derivados de 5-feniltiazol y uso como inhibidor de quinasa p i 3
AR037907A1 (es) Derivados de azaindolilalquilamina como ligandos de 5-hidroxitriptamina-6
CO6241115A2 (es) Compuestos y composiciones como inhibidores de protein quinasas
SE0201635D0 (sv) Novel compounds
AR055053A1 (es) Compuestos indol sustituidos con actividad inhibidora de nos. composiciones farmaceuticas.
AR052900A1 (es) Derivados de tiazol, un metodo para su preparacion, composiciones farmaceuticas que los contienen y su uso en la elaboracion de medicamentos para el tratamiento de enfermedades mediadas por ece-1
AR020165A1 (es) Derivados de pirimidinas sustituidas, su procedimiento de preparacion, composiciones farmaceuticas que las contienen y el uso de los mismos para la preparacion de medicamentos

Legal Events

Date Code Title Description
FA Abandonment or withdrawal